Initially, in vitro assays will be conducted to evaluate Avapritinib's inhibitory activity on PDGFRA and KIT mutants, along with its effects on cellular proliferation and apoptosis in NSCLC cell lines. Here, KIT is linked to non-small cell lung carcinoma.